Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy.

Autor: Vanoli F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Herviou L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tsuda Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sung P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Xie Z; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fishinevich E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Min SS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mallen W; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Wardin HT; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zhang Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jasin M; Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA., Antonescu CR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. antonesc@mskcc.org.

Publikováno v: Oncogenesis [Oncogenesis] 2023 Feb 17; Vol. 12 (1), pp. 8. Date of Electronic Publication: 2023 Feb 17.

Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates.

Autor: Dermawan JK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Vanoli F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Herviou L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sung YS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zhang L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Singer S; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tap WD; Department of Medicine, Sarcoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Benayed R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bale TA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Benhamida JK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dickson BC; Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada., Antonescu CR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. antonesc@mskcc.org.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2022 Aug; Vol. 35 (8), pp. 1055-1065. Date of Electronic Publication: 2022 Mar 28.

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.

Autor: Alaterre E; Department of Biological Hematology, CHU Montpellier, Montpellier, France.; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Ovejero S; Department of Biological Hematology, CHU Montpellier, Montpellier, France.; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Herviou L; Department of Biological Hematology, CHU Montpellier, Montpellier, France.; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., de Boussac H; Diag2Tec, Montpellier, France., Papadopoulos G; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Kulis M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain., Boireau S; Department of Biological Hematology, CHU Montpellier, Montpellier, France.; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Robert N; Department of Biological Hematology, CHU Montpellier, Montpellier, France.; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Requirand G; Department of Biological Hematology, CHU Montpellier, Montpellier, France.; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Bruyer A; Diag2Tec, Montpellier, France., Cartron G; Clinical Hematology. CHU Montpellier, Montpellier, France.; University of Montpellier, UFR Medicine, Montpellier, France.; UMR-CNRS 5535, Institut de Génétique Moléculaire de Montpellier, 34090 Montpellier, France., Vincent L; Clinical Hematology. CHU Montpellier, Montpellier, France., Martinez AM; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Martin-Subero JI; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.; Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Cavalli G; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Moreaux J; Department of Biological Hematology, CHU Montpellier, Montpellier, France.; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France.; University of Montpellier, UFR Medicine, Montpellier, France.; Institut Universitaire de France (IUF).

Publikováno v: Theranostics [Theranostics] 2022 Jan 16; Vol. 12 (4), pp. 1715-1729. Date of Electronic Publication: 2022 Jan 16 (Print Publication: 2022).

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.

Autor: Herviou L; IGH, CNRS, Univ Montpellier, Montpellier, France.; Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France.; University of Montpellier, 34090, Montpellier, France., Ovejero S; IGH, CNRS, Univ Montpellier, Montpellier, France.; Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France.; University of Montpellier, 34090, Montpellier, France., Izard F; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), 34298, Montpellier, France.; University of Montpellier, 34090, Montpellier, France., Karmous-Gadacha O; Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France., Gourzones C; IGH, CNRS, Univ Montpellier, Montpellier, France., Bellanger C; IGH, CNRS, Univ Montpellier, Montpellier, France., De Smedt E; Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium., Ma A; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Vincent L; Department of Clinical Hematology, CHU Montpellier, Montpellier, France., Cartron G; University of Montpellier, 34090, Montpellier, France.; Department of Clinical Hematology, CHU Montpellier, Montpellier, France., Jin J; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., De Bruyne E; Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium., Grimaud C; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), 34298, Montpellier, France.; University of Montpellier, 34090, Montpellier, France.; Centre National de La Recherche Scientifique (CNRS), 34293, Montpellier, France., Julien E; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), 34298, Montpellier, France. eric.julien@inserm.fr.; University of Montpellier, 34090, Montpellier, France. eric.julien@inserm.fr.; Centre National de La Recherche Scientifique (CNRS), 34293, Montpellier, France. eric.julien@inserm.fr., Moreaux J; IGH, CNRS, Univ Montpellier, Montpellier, France. jerome.moreaux@igh.cnrs.fr.; Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France. jerome.moreaux@igh.cnrs.fr.; University of Montpellier, 34090, Montpellier, France. jerome.moreaux@igh.cnrs.fr.; Institut Universitaire de France (IUF), Paris, France. jerome.moreaux@igh.cnrs.fr.

Publikováno v: Clinical epigenetics [Clin Epigenetics] 2021 Sep 16; Vol. 13 (1), pp. 174. Date of Electronic Publication: 2021 Sep 16.